Showing 1 - 3 results of 3 for search 'Michal Geva', query time: 0.01s Refine Results
  1. 1
    In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease

    In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional bene... by Michal Geva, Ralf Reilmann, Robin Schubert, Kelly Chen, Y Paul Goldberg, Michael R. Hayden

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease (HD)

    The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease... by Michal Geva, Ralf Reilmann, Andrew Feigin, Anne Rosser, Sandra Kostyk, Kelly Chen, Yael Cohen, Y Paul Goldberg, Michael R. Hayden

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial

    Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial by Michal Geva, Y Paul Goldberg, Melanie L. Leitner, Kelly Chen, Wei Feng, Noga Gershoni Emek, James D. Berry, Sabrina Paganoni, Jeremy Shefner, Merit ECudkowicz, Michael R. Hayden

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: